Benefits
Cognitive function + memory + mood 18-month RCT (Small 2014 PIVOTAL)
Small 2014 (Am J Geriatr Psychiatry, doi:10.1016/j.jagp.2017.10.010) — randomized double-blind placebo-controlled 18-MONTH parallel trial. Middle-aged and older NON-DEMENTED ADULTS aged 50-90 with mild memory complaints. Theracurmin® 90 mg curcumin twice daily (180 mg/day) vs placebo. Memory performance + FDDNP-PET imaging measuring brain amyloid plaque + tau tangle deposition. RESULTS: SIGNIFICANT IMPROVEMENTS in MEMORY + ATTENTION + MOOD with Theracurmin. 27-fold higher blood concentration AUC documented. Foundational pivotal cognitive aging RCT. UCLA Gary Small lead investigator.
MCI and Alzheimer's stabilization 6-month trial (Theravalues study #4)
6-month trial in 93 patients with Alzheimer's disease and mild cognitive impairment. 17 MCI + 19 AD patients received daily Theracurmin®. Geriatric assessment: MoCA, ADL, MMSE. RESULTS: NON-TREATED patients showed DECLINE in MoCA, instrumental ADL, MMSE scores. TREATED patients' scores STAYED CONSTANT — disease stabilization. Important real-world evidence for AD/MCI populations though smaller sample. Stabilization vs decline is clinically meaningful in degenerative conditions.
NCT07251985 — UCLA 12-month Phase 2 cognitive trial (NOT_YET_RECRUITING)
NCT07251985 — UCLA-sponsored Phase 2 randomized parallel triple-masked clinical trial. Cognitive Effects of Bioavailable Curcumin. Theracurmin Super TS-P1 capsules containing 75 mg curcumin total taken twice daily (during breakfast and dinner) for 12 months. Conditions: Memory; Cognitive Function Decline. NOT_YET_RECRUITING — represents ongoing rigorous clinical development. Demonstrates continued institutional research interest beyond manufacturer.
NAFLD 3-month RCT — hs-CRP reduction
3-month nano-curcumin 80 mg/day RCT in NAFLD patients showed SIGNIFICANT REDUCTION in hs-CRP levels vs placebo (high-sensitivity C-reactive protein, key cardiovascular inflammation marker). NAFLD is common condition affecting 25-30% of adults with limited pharmacological options — clinical inflammation reduction relevant. Less robust than Small 2014 cognitive evidence but supportive.
Hemodialysis 12-week RCT — hs-CRP reduction
12-week supplementation 120 mg/day nano-curcumin in HEMODIALYSIS patients showed SIGNIFICANT REDUCTION in hs-CRP levels vs placebo. Mechanism: anti-inflammatory effects on chronic kidney disease inflammation. Important indication in dialysis-dependent population where systemic inflammation is significant clinical concern.
27-fold bioavailability advantage vs standard curcumin (mechanism)
Pharmacokinetic advantage: HEALTHY HUMAN VOLUNTEERS consuming 30 mg oral Theracurmin show 27-FOLD HIGHER AREA UNDER BLOOD CONCENTRATION-TIME CURVE values vs same volunteers consuming standard curcumin powder. Mechanism: colloidal nanoparticle dispersion enables intestinal endothelium penetration that standard curcumin (poorly water-soluble crystalline form) cannot achieve. Foundational PK distinguishing feature.
Coronary slow flow phenomenon trial — NEGATIVE counter-evidence
PMC11290174 — randomized double-blind clinical trial in coronary slow flow phenomenon (CSFP) patients. Nano-curcumin showed NO significant improvement in hs-CRP levels in CSFP patients. 24-week 180 mg Theracurmin in COPD patients ALSO did NOT improve hs-CRP significantly. Important honest counter-evidence — Theracurmin/nano-curcumin effects on inflammation may be condition-dependent, not universal. Evidence base shows mixed inflammation results across different patient populations.
Mechanism of action
Colloidal nanoparticle dispersion bioavailability (UNIQUE)
Theracurmin® is curcumin DISPERSED WITH COLLOIDAL NANOPARTICLES via Theravalues' proprietary process. UNIQUE among curcumin formulations — distinct from phytosome (Meriva), micellar (Longvida), curcumin-piperine (BCM-95), curcumin-fenugreek (CurQfen), or polysaccharide (Curcuwin). 27× AUC bioavailability over standard curcumin powder. Foundation PK distinguishing feature.
Increased intestinal endothelium penetrability
Nanoparticle dispersion dramatically improves intestinal absorption of normally poorly-soluble curcumin. Mechanism distinct from emulsification (oil-based) or chemical complex formation.
NF-κB anti-inflammatory pathway suppression
Curcumin core mechanism: suppresses NF-κB activation + pro-inflammatory cytokines + COX-2 + iNOS. Foundation anti-inflammatory mechanism. Higher bioavailability via Theracurmin enables clinically meaningful effects at lower doses.
BBB penetration with bioavailable form
Curcumin metabolites cross BBB to exert direct CNS effects: anti-amyloid, anti-tau, anti-inflammatory, BDNF modulation. Theracurmin bioavailability advantage enables clinically meaningful CNS exposure where standard curcumin may not.
Amyloid plaque + tau tangle modulation
Small 2014 FDDNP-PET imaging showed Theracurmin effects on AMYLOID PLAQUE + TAU TANGLE deposition in brain. Mechanism: curcumin direct effects on amyloid aggregation + tau hyperphosphorylation. Important for cognitive aging applications.
Antioxidant via direct ROS scavenging
Direct scavenging of hydroxyl, peroxyl, superoxide radicals + endogenous antioxidant defense enhancement (Nrf2 activation). Mechanism for multiple aging-related applications.
Clinical trials
Randomized double-blind placebo-controlled 18-month parallel trial (Small GW et al. 2018, Am J Geriatr Psychiatry, doi:10.1016/j.jagp.2017.10.010, PMID 29246725). UCLA Gary Small lead investigator.
Middle-aged and older NON-DEMENTED ADULTS aged 50-90 with mild memory complaints. Theracurmin® 90 mg curcumin twice daily (180 mg/day) vs placebo for 18 MONTHS. Memory performance + FDDNP-PET measuring brain amyloid plaque + tau tangle deposition.
SIGNIFICANT IMPROVEMENTS in MEMORY + ATTENTION + MOOD with Theracurmin vs placebo. 27-fold higher blood concentration AUC documented vs standard curcumin powder. PIVOTAL 18-month duration is one of LONGEST cognitive curcumin trials available. Foundational evidence supporting cognitive aging applications. UCLA-conducted with rigorous methodology.
6-month clinical trial in MCI and Alzheimer's disease patients (Theravalues research base).
93 patients with Alzheimer's disease and mild cognitive impairment underwent geriatric assessment at start and end of 6-month period. 17 MCI + 19 AD patients received daily Theracurmin®. MoCA, ADL, MMSE assessments.
NON-TREATED patients showed DECLINE in MoCA, instrumental ADL, MMSE scores. Theracurmin-TREATED patients' scores STAYED CONSTANT — disease stabilization. Smaller sample but clinically meaningful: stabilization vs decline in degenerative conditions. Important real-world AD/MCI evidence supporting Small 2014 findings.
Randomized parallel triple-masked Phase 2 clinical trial (NCT07251985, University of California Los Angeles).
Older adults with cognitive function decline + memory complaints. Theracurmin Super TS-P1 capsules containing 75 mg curcumin total taken twice daily for 12 months vs placebo.
NOT_YET_RECRUITING — represents ONGOING RIGOROUS Phase 2 development at UCLA. Continued institutional academic research interest beyond manufacturer. Will provide additional rigorous cognitive evidence for Theracurmin upon completion.
About this ingredient
Theracurmin® is a BRANDED HIGH-BIOAVAILABILITY CURCUMIN formulated as COLLOIDAL NANOPARTICLE DISPERSION manufactured by THERAVALUES CORPORATION (Tokyo, Japan). DISTINGUISHING TECHNOLOGY: curcumin (diferuloylmethane) dispersed with colloidal nanoparticles via Theravalues' proprietary manufacturing process. UNIQUE BIOAVAILABILITY: healthy human volunteers consuming 30 mg oral Theracurmin show 27-FOLD HIGHER AREA UNDER BLOOD CONCENTRATION-TIME CURVE values vs same volunteers consuming standard curcumin powder. 30 mg Theracurmin ≈ 810 mg standard curcumin equivalent. UNIQUE among curcumin formulations — distinct from PHYTOSOME (Meriva, Indena), MICELLAR (Longvida, Verdure), CURCUMIN-PIPERINE (BCM-95, Sabinsa), CURCUMIN-FENUGREEK (CurQfen, Akay), POLYSACCHARIDE (Curcuwin Ultra+, OmniActive), HYDROCURC (Pharmako). Mechanism: nanoparticle dispersion enables intestinal endothelium penetration that standard crystalline curcumin (poorly water-soluble) cannot achieve. PIVOTAL CLINICAL EVIDENCE: SMALL 2014 (Am J Geriatr Psychiatry, doi:10.1016/j.jagp.2017.10.010, PMID 29246725) PIVOTAL 18-MONTH COGNITIVE RCT — randomized double-blind placebo-controlled trial in middle-aged and older non-demented adults aged 50-90 with mild memory complaints. Theracurmin® 90 mg curcumin twice daily (180 mg/day) vs placebo for 18 MONTHS. Memory + attention + mood IMPROVEMENTS. FDDNP-PET imaging measuring brain amyloid plaque + tau tangle deposition. UCLA Gary Small lead investigator. THERAVALUES STUDY #4 — 6-MONTH MCI/AD STABILIZATION TRIAL (n=93) showing non-treated decline vs Theracurmin-treated stabilization in MoCA/ADL/MMSE. NCT07251985 UCLA-SPONSORED Phase 2 12-month cognitive trial NOT_YET_RECRUITING (Theracurmin Super TS-P1 75 mg/day for 12 months) — ongoing rigorous academic research. NAFLD 3-month 80 mg/day RCT — hs-CRP reduction. HEMODIALYSIS 12-week 120 mg/day RCT — hs-CRP reduction. IMPORTANT NEGATIVE: COPD 24-week 180 mg/day did NOT improve hs-CRP; CSFP trial (PMC11290174) ALSO did not improve hs-CRP — condition-dependent effects, not universal.
MECHANISMS: COLLOIDAL NANOPARTICLE DISPERSION bioavailability advantage (foundational PK mechanism); increased intestinal endothelium penetrability; NF-κB anti-inflammatory pathway suppression (curcumin core mechanism); BBB penetration with bioavailable form; AMYLOID PLAQUE + TAU TANGLE modulation (Small 2014 FDDNP-PET evidence); direct ROS scavenging + Nrf2 activation antioxidant. EVIDENCE: 3/5 reflects: (1) SMALL 2014 PIVOTAL 18-MONTH COGNITIVE RCT (longest cognitive curcumin trial) with FDDNP-PET amyloid/tau imaging, (2) THERAVALUES MCI/AD 6-month stabilization trial, (3) NCT07251985 UCLA Phase 2 12-month ongoing, (4) NAFLD + HEMODIALYSIS hs-CRP reduction RCTs, (5) WELL-CHARACTERIZED 27× bioavailability advantage vs standard curcumin, (6) MECHANISM-RICH FDDNP-PET amyloid/tau imaging supporting cognitive mechanism, (7) UCLA + academic research interest beyond manufacturer, (8) IMPORTANT NEGATIVE COPD + CSFP hs-CRP trials (condition-dependent effects), (9) industry-related evidence (Theravalues + UCLA collaboration) — important context. SAFETY: Excellent — 18-month Small 2014 trial supports long-term safety. Best positioned as: (a) COGNITIVE AGING + MILD MEMORY COMPLAINTS adjunct in middle-aged + older adults (Small 2014 PIVOTAL evidence), (b) MCI + EARLY ALZHEIMER'S stabilization adjunct (Theravalues 6-month trial), (c) NAFLD adjunct (hs-CRP reduction evidence), (d) HEMODIALYSIS chronic inflammation adjunct (hs-CRP evidence), (e) DAILY long-term use acceptable based on 18-month safety profile, (f) SUPERIOR BIOAVAILABILITY ALTERNATIVE to standard curcumin for those wanting clinical-grade curcumin effects, (g) DAILY 30-180 mg dose range much lower than standard curcumin (1-2 g) — practical advantage, (h) HONEST framing required given mixed inflammation results (positive in some conditions, negative in others). Honest framing: Theracurmin® has rigorous cognitive evidence — Small 2014 18-month PIVOTAL RCT with FDDNP-PET amyloid/tau imaging is methodologically robust evidence rare for curcumin formulations. The 27× bioavailability advantage vs standard curcumin is a genuine pharmacokinetic distinction supported by independent published research. UCLA's continued academic research interest (NCT07251985 Phase 2) supports beyond-manufacturer credibility. HONEST COUNTER-EVIDENCE: COPD and CSFP trials NEGATIVE on hs-CRP — Theracurmin inflammation effects are condition-dependent not universal. Cognitive evidence (Small 2014) more robust than universal anti-inflammatory effects. Reasonable cognitive aging adjunct based on evidence — particularly compelling for those wanting research-backed bioavailable curcumin formulation. Industry-related context (Theravalues + UCLA) warrants caveat but methodology consistently rigorous.